Till date, orthodox management therapies for kidney disorders have been embraced and identified to include the use of renal replacement therapy (dialysis and transplantation) and applications of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and erythropoietin to slow the progression of loss of kidney function [5]. This evidence concerns the gene ACE and kidney disorder.